Mercer Global Advisors Inc. ADV Sells 1,907 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mercer Global Advisors Inc. ADV trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 43.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,451 shares of the medical research company's stock after selling 1,907 shares during the quarter. Mercer Global Advisors Inc. ADV's holdings in Charles River Laboratories International were worth $452,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. D1 Capital Partners L.P. acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at about $172,752,000. Norges Bank acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $98,886,000. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $42,776,000. Finally, Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 17.1% in the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after purchasing an additional 151,159 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on CRL shares. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Robert W. Baird boosted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus price target of $176.00.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $144.38 on Wednesday. The business's fifty day moving average is $137.41 and its 200 day moving average is $165.78. The firm has a market cap of $7.09 billion, a price-to-earnings ratio of 962.53, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.27 earnings per share. Research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83% increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.